A Phase I/Ⅱa Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 Pneumonia
Latest Information Update: 12 Jan 2023
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia
- Focus Adverse reactions
- Sponsors Nature cell
- 25 Oct 2022 Status changed from not yet recruiting to recruiting.
- 21 Sep 2022 Planned End Date changed from 1 Apr 2023 to 1 Dec 2023.
- 21 Sep 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Nov 2023.